Topical Imiquimod in the Treatment of Conjunctival Actinic Keratosis.
Publication/Presentation Date
1-1-2017
Abstract
Conjunctival actinic keratosis is rare and difficult to treat, as recurrences are common. Imiquimod, an immune response modulator, is currently Food and Drug Administration-approved for cutaneous actinic keratosis and superficial basal cell carcinomas. Emerging reports have shown it to be effective in treating some periocular and conjunctival lesions. The authors present a case of a 68-year-old white man with recurrent actinic keratosis involving the pretarsal conjunctiva, which was successfully treated with 5% topical imiquimod following previous failure with cryotherapy and interferon α-2b. The patient had ocular irritation that resolved on cessation of treatment. To the authors' knowledge, this is the first report of conjunctival actinic keratosis being treated with and successfully eradicated by topical imiquimod.
Volume
33
Issue
1
First Page
21
Last Page
21
ISSN
1537-2677
Published In/Presented At
Rowlands, M. A., Giacometti, J. N., Servat, J., Materin, M. A., & Levin, F. (2017). Topical Imiquimod in the Treatment of Conjunctival Actinic Keratosis. Ophthalmic plastic and reconstructive surgery, 33(1), e21–e23. https://doi.org/10.1097/IOP.0000000000000432
Disciplines
Medicine and Health Sciences
PubMedID
25853505
Department(s)
Department of Medicine
Document Type
Article